Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Amble vs Aurelius Health Group

Amble
Graded #221

Higher grade

vs+3.200000000000003
Aurelius Health Group
Graded #275

Lower grade

The verdict

Amble takes it — 65.5/100 to 62.3/100.

Amble grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth weight loss provider offering compounded semaglutide and tiered tirzepatide programs.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
60
60
Dose & formulationAmble +12
64
52
Clinical oversightAmble +3
79
76
Labs & monitoringAurelius Health Group +11
52
63
FulfillmentAmble +20
81
61
Contract termsAurelius Health Group +6
55
61
Amble · left barAurelius Health Group · right bar

The numbers

MetricAmbleAurelius Health Group
WeighScore65.5/10062.3/100
GradeCC
Scorecard rank#221#275
Semaglutide$179/mo (starting dose, compounded)Not disclosed
Tirzepatide$289/mo (starting dose, compounded)$199/mo (microdose tier, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Amble

Graded #221 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Aurelius Health Group

Graded #275 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • Microdose-only model — sub-therapeutic doses have thinner trial evidence and likely smaller weight loss than full-dose tirzepatide
  • No semaglutide or standard full-dose option
  • No named compounding pharmacy partner
  • No state list and no named medical director or pharmacist-in-charge

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard